Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 33 | 2024 | 850 | 8.250 |
Why?
|
| Telemedicine | 5 | 2023 | 188 | 2.190 |
Why?
|
| Organ Transplantation | 3 | 2023 | 276 | 1.860 |
Why?
|
| Tissue and Organ Procurement | 4 | 2024 | 347 | 1.400 |
Why?
|
| Hepatitis C | 5 | 2023 | 172 | 1.350 |
Why?
|
| Hepatitis C, Chronic | 4 | 2021 | 91 | 1.260 |
Why?
|
| Transplant Recipients | 10 | 2024 | 137 | 1.230 |
Why?
|
| Tissue Donors | 7 | 2023 | 494 | 1.200 |
Why?
|
| Nephrology | 3 | 2024 | 41 | 1.140 |
Why?
|
| Graft Rejection | 7 | 2023 | 1070 | 1.050 |
Why?
|
| Polyomavirus Infections | 2 | 2021 | 28 | 0.980 |
Why?
|
| Tumor Virus Infections | 2 | 2021 | 81 | 0.960 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 312 | 0.900 |
Why?
|
| Norovirus | 1 | 2023 | 13 | 0.890 |
Why?
|
| Histoplasmosis | 1 | 2023 | 26 | 0.870 |
Why?
|
| Nephrologists | 3 | 2024 | 10 | 0.860 |
Why?
|
| Immunosuppressive Agents | 4 | 2024 | 975 | 0.800 |
Why?
|
| Polyomavirus | 1 | 2021 | 16 | 0.790 |
Why?
|
| Q Fever | 1 | 2021 | 8 | 0.790 |
Why?
|
| Coxiella burnetii | 1 | 2021 | 11 | 0.780 |
Why?
|
| Graft Survival | 5 | 2023 | 900 | 0.770 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 428 | 0.710 |
Why?
|
| Hematuria | 1 | 2020 | 50 | 0.700 |
Why?
|
| Pancreas Transplantation | 1 | 2020 | 104 | 0.680 |
Why?
|
| Kidney Diseases | 1 | 2021 | 319 | 0.640 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 420 | 0.630 |
Why?
|
| Humans | 43 | 2024 | 89349 | 0.620 |
Why?
|
| Kidney | 10 | 2023 | 1147 | 0.610 |
Why?
|
| Erythema | 1 | 2018 | 29 | 0.610 |
Why?
|
| Medication Adherence | 1 | 2019 | 140 | 0.600 |
Why?
|
| Hepacivirus | 7 | 2023 | 130 | 0.580 |
Why?
|
| Kidney Failure, Chronic | 4 | 2024 | 414 | 0.530 |
Why?
|
| Retrospective Studies | 10 | 2023 | 9057 | 0.410 |
Why?
|
| Living Donors | 7 | 2024 | 339 | 0.390 |
Why?
|
| United States | 7 | 2024 | 6987 | 0.390 |
Why?
|
| Patient Care Team | 1 | 2011 | 284 | 0.320 |
Why?
|
| Donor Selection | 2 | 2020 | 74 | 0.320 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 345 | 0.310 |
Why?
|
| Hemolysis | 1 | 2008 | 64 | 0.310 |
Why?
|
| Antiviral Agents | 5 | 2023 | 478 | 0.300 |
Why?
|
| Allografts | 4 | 2023 | 181 | 0.300 |
Why?
|
| Heart Valve Prosthesis | 1 | 2008 | 98 | 0.300 |
Why?
|
| Lung | 2 | 2024 | 1263 | 0.290 |
Why?
|
| Vascular Diseases | 1 | 2008 | 118 | 0.290 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2017 | 22 | 0.290 |
Why?
|
| Middle Aged | 11 | 2024 | 25974 | 0.290 |
Why?
|
| Adult | 13 | 2023 | 26607 | 0.270 |
Why?
|
| Aortic Valve | 1 | 2008 | 244 | 0.270 |
Why?
|
| Mitral Valve | 1 | 2008 | 262 | 0.270 |
Why?
|
| Male | 12 | 2024 | 42410 | 0.260 |
Why?
|
| Accreditation | 1 | 2024 | 62 | 0.220 |
Why?
|
| Histoplasma | 1 | 2023 | 14 | 0.220 |
Why?
|
| Hospice Care | 1 | 2023 | 40 | 0.220 |
Why?
|
| HLA Antigens | 2 | 2023 | 227 | 0.220 |
Why?
|
| Fellowships and Scholarships | 2 | 2024 | 122 | 0.220 |
Why?
|
| Time Factors | 3 | 2021 | 5337 | 0.210 |
Why?
|
| Antifungal Agents | 1 | 2023 | 120 | 0.210 |
Why?
|
| Central Nervous System | 1 | 2023 | 153 | 0.200 |
Why?
|
| Diarrhea | 1 | 2023 | 182 | 0.200 |
Why?
|
| Metabolic Syndrome | 1 | 2023 | 123 | 0.200 |
Why?
|
| Terminal Care | 1 | 2023 | 137 | 0.200 |
Why?
|
| BK Virus | 1 | 2021 | 23 | 0.200 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 43 | 0.200 |
Why?
|
| Female | 11 | 2023 | 46200 | 0.190 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 120 | 0.190 |
Why?
|
| Histocompatibility | 1 | 2021 | 66 | 0.190 |
Why?
|
| Referral and Consultation | 2 | 2020 | 341 | 0.190 |
Why?
|
| Hospital Departments | 1 | 2020 | 13 | 0.180 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2020 | 5 | 0.180 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2020 | 60 | 0.180 |
Why?
|
| Videoconferencing | 1 | 2020 | 15 | 0.180 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 219 | 0.180 |
Why?
|
| Liver | 2 | 2023 | 1208 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 851 | 0.170 |
Why?
|
| Isoantibodies | 1 | 2021 | 119 | 0.170 |
Why?
|
| Antilymphocyte Serum | 1 | 2019 | 70 | 0.170 |
Why?
|
| Muromonab-CD3 | 1 | 2019 | 69 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 393 | 0.170 |
Why?
|
| Alemtuzumab | 1 | 2019 | 85 | 0.170 |
Why?
|
| Lymphocyte Depletion | 1 | 2019 | 98 | 0.170 |
Why?
|
| Fever | 1 | 2020 | 128 | 0.170 |
Why?
|
| Logistic Models | 2 | 2020 | 1213 | 0.170 |
Why?
|
| Postoperative Care | 1 | 2020 | 231 | 0.170 |
Why?
|
| Geography | 1 | 2020 | 227 | 0.160 |
Why?
|
| Registries | 2 | 2021 | 784 | 0.160 |
Why?
|
| Social Media | 1 | 2020 | 95 | 0.160 |
Why?
|
| Program Evaluation | 1 | 2020 | 307 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2020 | 396 | 0.150 |
Why?
|
| Risk Factors | 4 | 2023 | 5498 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 260 | 0.150 |
Why?
|
| Acute Disease | 1 | 2019 | 841 | 0.150 |
Why?
|
| Pandemics | 1 | 2023 | 773 | 0.150 |
Why?
|
| Bortezomib | 1 | 2017 | 82 | 0.140 |
Why?
|
| Proteinuria | 1 | 2017 | 67 | 0.140 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 2623 | 0.140 |
Why?
|
| Sex Factors | 1 | 2019 | 1066 | 0.130 |
Why?
|
| Patient Selection | 1 | 2020 | 684 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 969 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2023 | 1180 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 601 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1412 | 0.130 |
Why?
|
| Age Factors | 1 | 2019 | 1870 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 560 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2661 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1046 | 0.110 |
Why?
|
| Viremia | 2 | 2023 | 49 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1840 | 0.100 |
Why?
|
| Young Adult | 2 | 2023 | 6312 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1176 | 0.100 |
Why?
|
| Waiting Lists | 2 | 2024 | 184 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 890 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 254 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 1668 | 0.080 |
Why?
|
| Aged | 4 | 2023 | 19165 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 996 | 0.080 |
Why?
|
| RNA | 2 | 2023 | 580 | 0.080 |
Why?
|
| Renal Dialysis | 2 | 2021 | 335 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2415 | 0.060 |
Why?
|
| Pregnancy | 1 | 2011 | 3018 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2024 | 92 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 4289 | 0.060 |
Why?
|
| Calcineurin Inhibitors | 1 | 2023 | 53 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 293 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2024 | 369 | 0.050 |
Why?
|
| Ezetimibe | 1 | 2021 | 35 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 281 | 0.050 |
Why?
|
| Palliative Care | 1 | 2023 | 264 | 0.050 |
Why?
|
| Delayed Graft Function | 1 | 2021 | 13 | 0.050 |
Why?
|
| Pulsatile Flow | 1 | 2020 | 50 | 0.050 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2020 | 59 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 481 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 130 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 146 | 0.040 |
Why?
|
| Perfusion | 1 | 2020 | 236 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 871 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 51 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1767 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 8241 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 152 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 344 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 463 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 988 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1072 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 742 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1184 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2303 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1723 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3666 | 0.020 |
Why?
|
| Adolescent | 1 | 2023 | 9263 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 3783 | 0.020 |
Why?
|